Edition:
India

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

27.68CNY
12:29pm IST
Change (% chg)

¥-0.07 (-0.25%)
Prev Close
¥27.75
Open
¥27.88
Day's High
¥28.22
Day's Low
¥27.33
Volume
7,663,654
Avg. Vol
7,511,123
52-wk High
¥31.87
52-wk Low
¥18.09

Chart for

About

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine... (more)

Overall

Beta: 0.80
Market Cap(Mil.): ¥23,372.63
Shares Outstanding(Mil.): 1,042.49
Dividend: 0.18
Yield (%): 0.80

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Zhejiang Huahai Pharmaceutical to invest in pharma industry park project

* Says it plans to invest in pharma industry park project with total investment at about 10 billion yuan ($1.50 billion)

29 Oct 2017

BRIEF-Zhejiang Huahai Pharmaceutical passes U.S. FDA approval

* Says it received approval for a kind of tablet, which is used for treatment of chronic hepatitis B, from U.S. Food and Drug Administration

13 Oct 2017

BRIEF-Zhejiang Huahai Pharmaceutical passes FDA approval

* Says it received approval for its production base of API from U.S Food and Drug Administration

28 Sep 2017

BRIEF-Zhejiang Huahai Pharmaceutical to use $30 mln to acquire shares of Eutilex

* Says co signs agreement to invest $30 million in Eutilex Co.,Ltd, which is mainly engaged in R&D of T cell therapy and antibody therapy products

05 Sep 2017

BRIEF-Zhejiang Huahai Pharmaceutical passes U.S. FDA approval

* Says it received FDA approval for Paroxetine Capsules from U.S Food and Drug Administration

22 Aug 2017

BRIEF-Zhejiang Huahai Pharma's prelim H1 net profit up 14.05 pct y/y

* Says preliminary H1 net profit up 14.05 percent y/y at 295.25 million yuan ($43.73 million)

26 Jul 2017

Earnings vs. Estimates